Results 241 to 250 of about 58,375 (292)
Some of the next articles are maybe not open access.
2022
The main purpose of this book is to create a reference for the indications, contraindications, patient selection, treatment practice, treatment side effect management, and follow-up of radionuclide treatments.Besides standard methods such as surgery, chemotherapy, radiotherapy, and hormone therapy, newly developed biological treatments, targeted ...
POLACK, BERNA +2 more
+13 more sources
The main purpose of this book is to create a reference for the indications, contraindications, patient selection, treatment practice, treatment side effect management, and follow-up of radionuclide treatments.Besides standard methods such as surgery, chemotherapy, radiotherapy, and hormone therapy, newly developed biological treatments, targeted ...
POLACK, BERNA +2 more
+13 more sources
Clinical Oncology, 1999
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment.
R B, Buchanan, V J, Lewington
openaire +5 more sources
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment.
R B, Buchanan, V J, Lewington
openaire +5 more sources
Radionuclide therapy revisited
European Journal of Nuclear Medicine, 1991Apart from its use in endocrinology and rheumatology, therapeutic nuclear medicine is developing rapidly as an additional treatment modality in oncology. Many different specific tumour-seeking radiopharmaceuticals are being applied both for diagnostic scintigraphy and treatment, using multiple routes and mechanisms to target radionuclides at tumours ...
openaire +2 more sources
Annals of Nuclear Medicine, 1998
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +2 more sources
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +2 more sources
Physics Today, 2000
Each year in the US, about 200 000 patients receive therapy with radionuclides, most commonly in the form of sealed sources for treating gynecological and head and neck cancers and radiopharmaceuticals for treating thyroid cancer. Known as brachytherapy, this kind of treatment has attracted a resurgence of interest in the medical world, primarily ...
Bert M. Coursey, Ravinder Nath
openaire +1 more source
Each year in the US, about 200 000 patients receive therapy with radionuclides, most commonly in the form of sealed sources for treating gynecological and head and neck cancers and radiopharmaceuticals for treating thyroid cancer. Known as brachytherapy, this kind of treatment has attracted a resurgence of interest in the medical world, primarily ...
Bert M. Coursey, Ravinder Nath
openaire +1 more source
Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Current Topics in Medicinal Chemistry, 2013The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide.
J L, Parus, R, Mikolajczak
openaire +2 more sources
2009
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Radionuclide therapy beyond radioiodine
Wiener Medizinische Wochenschrift, 2012For decades, Iodine-131 has been used for the treatment of patients with thyroid cancer. In recent years, increasingly, other radiopharmaceuticals are in clinical use in the treatment of various malignant diseases. Although in principle these therapies-as in all applications of radionuclides-special radiation protection measures are required, a ...
openaire +2 more sources
2008
Clinical applications of targeted radionuclide treatment have evolved considerably over the last 10–20 years, principally as a result of an improved understanding of tumour biology, and the identification of biochemical pathways and protein targets expressed preferentially on tumours compared to normal tissue.
Andrew M. Scott, Sze-Ting Lee
openaire +1 more source
Clinical applications of targeted radionuclide treatment have evolved considerably over the last 10–20 years, principally as a result of an improved understanding of tumour biology, and the identification of biochemical pathways and protein targets expressed preferentially on tumours compared to normal tissue.
Andrew M. Scott, Sze-Ting Lee
openaire +1 more source